Enterprise Value

5.888B

Cash

710.6M

Avg Qtr Burn

-109.2M

Short % of Float

7.63%

Insider Ownership

0.80%

Institutional Own.

-

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
AYVAKIT (avapritinib) Details
PDGFRA mutant GIST (Gastrointestinal Stromal Tumors)

Approved

Quarterly sales

GAVRETO (parlsetinib) Details
RET+ NSCLC (Non-small cell lung cancer), RET+ Thyroid cancer, solid tumors

Approved

Quarterly sales

Approved

Quarterly sales

BLU-222 (CDK12) Details
Cancer, Breast cancer

Phase 1/2

Update

BLU-451 Details
Solid tumor/s, Non-small cell lung carcinoma, Cancer

Phase 1/2

Update

BLU-945 +/- osimertinib Details
Solid tumor/s, Non-small cell lung carcinoma, Cancer

Phase 1/2

Update

Elenestinib Details
Systemic Mastocytosis

Phase 1

Data readout